



December 29, 2017

Web Announcement 1493

Drug Use Review (DUR) Board Approves Changes Effective January 1, 2018

The Nevada Medicaid Drug Use Review (DUR) Board met on August 24, 2017, and voted to adopt the following changes, which will be effective January 1, 2018:

Drug Class/Program	Changes
COX-II Inhibitors (Celebrex®)	Prior Authorization Criteria removed
Targeted Immunomodulators	List of products updated to include Siliq® (brodalumab)
Exondys 51® (eteplirsen)	Added prior authorization criteria
Spinraza® (nusinersen)	Added prior authorization criteria